EXEL (exelixis.com) Koefisien nilai perusahaan marang pendapatan

Simbol resmi perusahaan Exelixis Inc (EXEL)

Exelixis, Inc. (EXEL) funds the search for new molecules using profits from its flagship drug. On GURU.Markets, the company's price-to-sales multiple shows a peak, where the 6141.08 mark indicates the level of investor confidence. While risks are tied to patent expirations, expanding the application of therapy for advanced renal cell carcinoma helps the brand maintain its leadership in the precision oncology sector.

exelixis.com (EXEL): Multiplikator EV/Sales saka 23.11.2025 nganti 20.11.2026

Rincian metrik keuangan lan pasar Exelixis (EXEL)

- rega lan prakiraan konsensus rega:
- indikator valuasi pasar bisnis:
Pambiji fundamental perusahaan:Exelixis, Inc. EXEL
Sampel barang exelixis.com

Steady demand for Cabometyx provides Exelixis, Inc. (EXEL) with high operational efficiency and a sustainable cash flow. The company's EV/Sales ratio compares the total enterprise value, including debt, with sales volume, allowing for a valuation of the market price of one dollar of revenue without distortions from the capital structure. This chart confirms the asset's fundamental reliability, supporting a premium valuation driven by the exceptional margins of targeted therapy.